FDA Mandates Safety Warnings for GLP-1 Drugs Over Potential Vision Loss Risk
The U.S. Food and Drug Administration (FDA) is requiring manufacturers of all GLP-1 medications to include new safety warnings regarding a potential link to nonarteritic anterior ischemic optic neuropathy (NAION). This rare condition involves decreased blood flow to the optic nerve and can lead to sudden, permanent vision loss. An analysis of 126 clinical trials involving over 134,000 patients revealed a higher incidence of NAION among GLP-1 users—6.4 cases per 100,000 patient-years compared to 3.8 in control groups. While the FDA noted that a definitive causal relationship has not yet been established, reports of the condition have surfaced across all currently marketed GLP-1 products.
Topics: drug safety FDA regulation GLP-1 medications NAION vision loss risk